Cancer Research Cancer Epigenetics Telomeres
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow Supplementary Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fernández, Y.
Right arrow Articles by Soengas, M. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fernández, Y.
Right arrow Articles by Soengas, M. S.
[Cancer Research 65, 6294-6304, July 15, 2005]
© 2005 American Association for Cancer Research

Experimental Therapeutics, Molecular Targets, and Chemical Biology

Differential Regulation of Noxa in Normal Melanocytes and Melanoma Cells by Proteasome Inhibition: Therapeutic Implications

Yolanda Fernández1, Monique Verhaegen1, Thomas P. Miller1, Jenny L. Rush2, Philipp Steiner4, Anthony W. Opipari, Jr.3, Scott W. Lowe5 and María S. Soengas1

Departments of 1 Dermatology, 2 Chemistry, and 3 Obstetrics and Gynecology, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan; 4 Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts; and 5 Cold Spring Harbor Laboratory, Cold Spring Harbor, New York

Requests for reprints: María S. Soengas, University of Michigan Comprehensive Cancer Center (4217 CCGC), 1500 East Medical Center Drive, Ann Arbor, MI 48109. Phone: 734-936-5643; Fax: 734-647-9654; E-mail: soengas{at}umich.edu.

Melanoma is the most aggressive form of skin cancer and advanced stages are invariably resistant to conventional therapeutic agents. Using bortezomib as a prototypic proteasome inhibitor, we have identified a novel and critical role of the proteasome in the maintenance of the malignant phenotype of melanoma cells that could have direct translational implications. Thus, melanoma cells from early, intermediate, and late stages of the disease could not sustain proteasome inhibition and underwent an effective activation of caspase-dependent and -independent death programs. This effect was tumor cell selective, because under similar conditions, normal melanocytes remained viable. Intriguingly, and despite of interfering with a cellular machinery in charge of controlling the half-life of the vast majority of cellular proteins, bortezomib did not promote a generalized disruption of melanoma-associated survival factors (including NF-{kappa}B, Bcl-2, Bcl-xL, XIAP, TRAF-2, or FLIP). Instead, we identified a dramatic induction in vitro and in vivo of the BH3-only protein Noxa in melanoma cells (but not in normal melanocytes) in response to proteasome inhibition. RNA interference validated a critical role of Noxa for the cytotoxic effect of bortezomib. Notably, the proteasome-dependent regulation of Noxa was found to extend to other tumor types, and it could not be recapitulated by standard chemotherapeutic drugs. In summary, our results revealed Noxa as a new biomarker to gauge the efficacy of bortezomib specifically in tumor cells, and provide a new strategy to overcome tumor chemoresistance.




This article has been cited by other articles:


Home page
 BloodHome page
F. Parlati, S. J. Lee, M. Aujay, E. Suzuki, K. Levitsky, J. B. Lorens, D. R. Micklem, P. Ruurs, C. Sylvain, Y. Lu, et al.
Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome
Blood, October 15, 2009; 114(16): 3439 - 3447.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. S. Khodadoust, M. Verhaegen, F. Kappes, E. Riveiro-Falkenbach, J. C. Cigudosa, D. S.L. Kim, A. M. Chinnaiyan, D. M. Markovitz, and M. S. Soengas
Melanoma Proliferation and Chemoresistance Controlled by the DEK Oncogene
Cancer Res., August 15, 2009; 69(16): 6405 - 6413.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
E. Lomonosova, J. Ryerse, and G. Chinnadurai
BAX/BAK-Independent Mitoptosis during Cell Death Induced by Proteasome Inhibition?
Mol. Cancer Res., August 1, 2009; 7(8): 1268 - 1284.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. DiFeo, F. Huang, J. Sangodkar, E. A. Terzo, D. Leake, G. Narla, and J. A. Martignetti
KLF6-SV1 Is a Novel Antiapoptotic Protein That Targets the BH3-Only Protein NOXA for Degradation and Whose Inhibition Extends Survival in an Ovarian Cancer Model
Cancer Res., June 1, 2009; 69(11): 4733 - 4741.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. L. Hodge, J. Yang, M. D. Buschman, P. M. Schaughency, H. Dang, W. Bere, Y. Yang, R. Savan, J. J. Subleski, X.-M. Yin, et al.
Interleukin-15 Enhances Proteasomal Degradation of Bid in Normal Lymphocytes: Implications for Large Granular Lymphocyte Leukemias
Cancer Res., May 1, 2009; 69(9): 3986 - 3994.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
Q. Wang, H. Mora-Jensen, M. A. Weniger, P. Perez-Galan, C. Wolford, T. Hai, D. Ron, W. Chen, W. Trenkle, A. Wiestner, et al.
ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells
PNAS, February 17, 2009; 106(7): 2200 - 2205.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Roue, M. Lopez-Guerra, P. Milpied, P. Perez-Galan, N. Villamor, E. Montserrat, E. Campo, and D. Colomer
Bendamustine Is Effective in p53-Deficient B-Cell Neoplasms and Requires Oxidative Stress and Caspase-Independent Signaling
Clin. Cancer Res., November 1, 2008; 14(21): 6907 - 6915.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
G. B. Lesinski, E. T. Raig, K. Guenterberg, L. Brown, M. R. Go, N. N. Shah, A. Lewis, M. Quimper, E. Hade, G. Young, et al.
IFN-{alpha} and Bortezomib Overcome Bcl-2 and Mcl-1 Overexpression in Melanoma Cells by Stimulating the Extrinsic Pathway of Apoptosis
Cancer Res., October 15, 2008; 68(20): 8351 - 8360.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. T. Nawrocki, J. S. Carew, K. H. Maclean, J. F. Courage, P. Huang, J. A. Houghton, J. L. Cleveland, F. J. Giles, and D. J. McConkey
Myc regulates aggresome formation, the induction of Noxa, and apoptosis in response to the combination of bortezomib and SAHA
Blood, October 1, 2008; 112(7): 2917 - 2926.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. Lioni, K. Noma, A. Snyder, A. Klein-Szanto, J. A. Diehl, A. K. Rustgi, M. Herlyn, and K. S.M. Smalley
Bortezomib induces apoptosis in esophageal squamous cell carcinoma cells through activation of the p38 mitogen-activated protein kinase pathway
Mol. Cancer Ther., September 1, 2008; 7(9): 2866 - 2875.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C. Sheridan, G. Brumatti, and S. J. Martin
Oncogenic B-RafV600E Inhibits Apoptosis and Promotes ERK-dependent Inactivation of Bad and Bim
J. Biol. Chem., August 8, 2008; 283(32): 22128 - 22135.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
N. Doudican, A. Rodriguez, I. Osman, and S. J. Orlow
Mebendazole Induces Apoptosis via Bcl-2 Inactivation in Chemoresistant Melanoma Cells
Mol. Cancer Res., August 1, 2008; 6(8): 1308 - 1315.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. E. Lovat, M. Corazzari, J. L. Armstrong, S. Martin, V. Pagliarini, D. Hill, A. M. Brown, M. Piacentini, M. A. Birch-Machin, and C. P.F. Redfern
Increasing Melanoma Cell Death Using Inhibitors of Protein Disulfide Isomerases to Abrogate Survival Responses to Endoplasmic Reticulum Stress
Cancer Res., July 1, 2008; 68(13): 5363 - 5369.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
A. Sekulic, P. Haluska Jr, A. J. Miller, J. G. De Lamo, S. Ejadi, J. S. Pulido, D. R. Salomao, E. C. Thorland, R. G. Vile, D. L. Swanson, et al.
Malignant Melanoma in the 21st Century: The Emerging Molecular Landscape
Mayo Clin. Proc., July 1, 2008; 83(7): 825 - 846.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Tse, A. R. Shoemaker, J. Adickes, M. G. Anderson, J. Chen, S. Jin, E. F. Johnson, K. C. Marsh, M. J. Mitten, P. Nimmer, et al.
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
Cancer Res., May 1, 2008; 68(9): 3421 - 3428.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
M. A. Nikiforov, M. Riblett, W.-H. Tang, V. Gratchouck, D. Zhuang, Y. Fernandez, M. Verhaegen, S. Varambally, A. M. Chinnaiyan, A. J. Jakubowiak, et al.
Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition
PNAS, December 4, 2007; 104(49): 19488 - 19493.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Voortman, E. F. Smit, R. Honeywell, B. C. Kuenen, G. J. Peters, H. van de Velde, and G. Giaccone
A Parallel Dose-Escalation Study of Weekly and Twice-Weekly Bortezomib in Combination with Gemcitabine and Cisplatin in the First-Line Treatment of Patients with Advanced Solid Tumors
Clin. Cancer Res., June 15, 2007; 13(12): 3642 - 3651.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. Han, L. A. Goldstein, W. Hou, and H. Rabinowich
Functional Linkage between NOXA and Bim in Mitochondrial Apoptotic Events
J. Biol. Chem., June 1, 2007; 282(22): 16223 - 16231.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. Voortman, A. Checinska, G. Giaccone, J. A. Rodriguez, and F. A.E. Kruyt
Bortezomib, but not cisplatin, induces mitochondria-dependent apoptosis accompanied by up-regulation of noxa in the non-small cell lung cancer cell line NCI-H460
Mol. Cancer Ther., March 1, 2007; 6(3): 1046 - 1053.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Meister, U. Schubert, K. Neubert, K. Herrmann, R. Burger, M. Gramatzki, S. Hahn, S. Schreiber, S. Wilhelm, M. Herrmann, et al.
Extensive Immunoglobulin Production Sensitizes Myeloma Cells for Proteasome Inhibition
Cancer Res., February 15, 2007; 67(4): 1783 - 1792.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
L. A. Smit, D. Y.H. Hallaert, R. Spijker, B. de Goeij, A. Jaspers, A. P. Kater, M. H.J. van Oers, C. J.M. van Noesel, and E. Eldering
Differential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity
Blood, February 15, 2007; 109(4): 1660 - 1668.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Verhaegen, J. A. Bauer, C. Martin de la Vega, G. Wang, K. G. Wolter, J. C. Brenner, Z. Nikolovska-Coleska, A. Bengtson, R. Nair, J. T. Elder, et al.
A Novel BH3 Mimetic Reveals a Mitogen-Activated Protein Kinase-Dependent Mechanism of Melanoma Cell Death Controlled by p53 and Reactive Oxygen Species
Cancer Res., December 1, 2006; 66(23): 11348 - 11359.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
O. Kwon, K. A Kim, S. O. Kim, R. Ha, W. K. Oh, M. S. Kim, H. S. Kim, G. D. Kim, J. W. Kim, M. Jung, et al.
NF-{kappa}B inhibition increases chemosensitivity to trichostatin A-induced cell death of Ki-Ras-transformed human prostate epithelial cells
Carcinogenesis, November 1, 2006; 27(11): 2258 - 2268.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Hur, D. W. Bell, K. L. Dean, K. R. Coser, P. C. Hilario, R. A. Okimoto, E. M. Tobey, S. L. Smith, K. J. Isselbacher, and T. Shioda
Regulation of Expression of BIK Proapoptotic Protein in Human Breast Cancer Cells: p53-Dependent Induction of BIK mRNA by Fulvestrant and Proteasomal Degradation of BIK Protein.
Cancer Res., October 15, 2006; 66(20): 10153 - 10161.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J.-Z. Qin, H. Xin, L. A. Sitailo, M. F. Denning, and B. J. Nickoloff
Enhanced Killing of Melanoma Cells by Simultaneously Targeting Mcl-1 and NOXA
Cancer Res., October 1, 2006; 66(19): 9636 - 9645.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
C. S. Mitsiades, D. McMillin, V. Kotoula, V. Poulaki, C. McMullan, J. Negri, G. Fanourakis, S. Tseleni-Balafouta, K. B. Ain, and N. Mitsiades
Antitumor Effects of the Proteasome Inhibitor Bortezomib in Medullary and Anaplastic Thyroid Carcinoma Cells in Vitro
J. Clin. Endocrinol. Metab., October 1, 2006; 91(10): 4013 - 4021.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
E. Aleo, C. J. Henderson, A. Fontanini, B. Solazzo, and C. Brancolini
Identification of new compounds that trigger apoptosome-independent caspase activation and apoptosis.
Cancer Res., September 15, 2006; 66(18): 9235 - 9244.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
X. Dolcet, D. Llobet, M. Encinas, J. Pallares, A. Cabero, J. A. Schoenenberger, J. X. Comella, and X. Matias-Guiu
Proteasome Inhibitors Induce Death but Activate NF-{kappa}B on Endometrial Carcinoma Cell Lines and Primary Culture Explants
J. Biol. Chem., August 4, 2006; 281(31): 22118 - 22130.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. A. Sosman and I. Puzanov
Molecular targets in melanoma from angiogenesis to apoptosis.
Clin. Cancer Res., April 1, 2006; 12(7): 2376s - 2383s.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Y. Fernandez, T. P. Miller, C. Denoyelle, J. A. Esteban, W.-H. Tang, A. L. Bengston, and M. S. Soengas
Chemical Blockage of the Proteasome Inhibitory Function of Bortezomib: IMPACT ON TUMOR CELL DEATH
J. Biol. Chem., January 13, 2006; 281(2): 1107 - 1118.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
G. C. Shore and J. Viallet
Modulating the Bcl-2 Family of Apoptosis Suppressors for Potential Therapeutic Benefit in Cancer
Hematology, January 1, 2005; 2005(1): 226 - 230.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2005 by the American Association for Cancer Research.